Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Opalesque Radio

Investing in Illiquid Collateralised Reinsurance Contracts vs. Cat Bonds
Radio Feature 82: Sona Blessing in conversation with Michael Stahel
 
Monday, August 12, 2013
radio Michael Stahel is a partner and portfolio manager at LGT Insurance-Linked Strategies in Switzerland, which has already raised USD 400 million from three pension fund mandates this year.

He played a key role in LGT’s acquisition of Clariden Leu’s Insurance-Linked Investments boutique in Q1 2012. In his current role, Michael maintains the responsibility for the main investment strategy for all insurance-linked funds and mandates.

In this podcast he elaborates on market developments within the insurance linked securities space and shares his insights on the observed shift towards investing in illiquid collateralised reinsurance contracts...

 Download this feature as MP3 (31.35 MB)

 
Listen to the complete feature
Investing in Illiquid Collateralised Reinsurance Contracts vs. Cat Bonds

Duration: 13:42 

  logo

Or listen to selected sub-features
  • Q1 - Can you give us a sense of and update us on the developments in the insurance linked securities space

    Duration: 02:33 


  • Q2 - What sort of "hazards" (life/non-life) are being reinsured?
    Could you elaborate on the catastrophe - natural/man made; geography; pandemic?

    Duration: 02:19 


  • Q3 - From the perspective of an investment manager, why is it more challenging to enter into direct contractual agreements?

    Duration: 01:41 


  • Q4 - Beyond pension plans, which other investors are investing in insurance linked strategies? What is the duration and expected yield for such an investment?

    Duration: 01:48 


  • Q5 - Could you elaborate on the differences, and also compare the duration and expected yield of investing in illiquid collateralised reinsurance contracts vs. for e.g. in "liquid" cat bonds?

    Duration: 01:53 


  • Q6 - Is there a capturable illiquidity risk premium and would you say it is commensurate?

    Duration: 01:03 


  • Q7 - What is the scope of investing in such strategies, and what is the investible market capacity going forward?

    Duration: 02:25 



Radio Link
  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for